Next Article in Journal
Diphlorethohydroxycarmalol Inhibits Interleukin-6 Production by Regulating NF-κB, STAT5 and SOCS1 in Lipopolysaccharide-Stimulated RAW264.7 Cells
Previous Article in Journal
Astaxanthin Attenuates Early Acute Kidney Injury Following Severe Burns in Rats by Ameliorating Oxidative Stress and Mitochondrial-Related Apoptosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antifungal Compounds from Cyanobacteria

1
Department of Food and Environmental Sciences, Viikki Biocenter 1, University of Helsinki, FI-00014, Helsinki, Finland
2
Program in Structural Biology and Biophysics, Institute of Biotechnology/Nuclear Magnetic Resonance Laboratory, University of Helsinki, FI-00014, Helsinki, Finland
3
Center for Nuclear Energy in Agriculture, University of São Paulo, Avenida Centenário 303, Piracicaba, 13400-970, São Paulo, Brazil
*
Author to whom correspondence should be addressed.
Mar. Drugs 2015, 13(4), 2124-2140; https://doi.org/10.3390/md13042124
Submission received: 30 January 2015 / Revised: 24 March 2015 / Accepted: 26 March 2015 / Published: 13 April 2015

Abstract

:
Cyanobacteria are photosynthetic prokaryotes found in a range of environments. They are infamous for the production of toxins, as well as bioactive compounds, which exhibit anticancer, antimicrobial and protease inhibition activities. Cyanobacteria produce a broad range of antifungals belonging to structural classes, such as peptides, polyketides and alkaloids. Here, we tested cyanobacteria from a wide variety of environments for antifungal activity. The potent antifungal macrolide scytophycin was detected in Anabaena sp. HAN21/1, Anabaena cf. cylindrica PH133, Nostoc sp. HAN11/1 and Scytonema sp. HAN3/2. To our knowledge, this is the first description of Anabaena strains that produce scytophycins. We detected antifungal glycolipopeptide hassallidin production in Anabaena spp. BIR JV1 and HAN7/1 and in Nostoc spp. 6sf Calc and CENA 219. These strains were isolated from brackish and freshwater samples collected in Brazil, the Czech Republic and Finland. In addition, three cyanobacterial strains, Fischerella sp. CENA 298, Scytonema hofmanni PCC 7110 and Nostoc sp. N107.3, produced unidentified antifungal compounds that warrant further characterization. Interestingly, all of the strains shown to produce antifungal compounds in this study belong to Nostocales or Stigonematales cyanobacterial orders.

1. Introduction

Cyanobacteria are photosynthetic cosmopolitan prokaryotic organisms that have been isolated from aquatic (freshwater, brackish and marine), terrestrial (soil, lichen-associated and the surface of leaves), and different aquatic and terrestrial extreme environments (hot springs, high salinity, deserts) [1,2]. In these environments, cyanobacteria face competitors and predators, including parasitic fungi, such as chytrids. The production of oligopeptides by Planktothrix spp. is believed to contribute to the defense against chytrid fungi [3,4]. Antifungal compounds have been previously detected in cyanobacterial extracts, such as fischerellin A, hapalindole, hassallidin/balticidins, carazostatin, phytoalexin, tolytoxin, scytophycin, toyocamycin, tjipanazole, nostocyclamide, nostodione and nostofungicidine [5,6,7]. Most of these compounds are synthetized by ribosomal pathways or by nonribosomal pathways. Examples of enzymes involved in the nonribosomal pathways are nonribosomal peptide synthetase (NRPS), polyketides synthases (PKS) or hybrid systems of both NRPS/PKS. The NRPSs and PKSs are multifunction modular enzymes involved in the synthesis of nonribosomal peptides and polyketides [8,9]. In cyanobacteria, the antifungal hassallidin is synthesized by NRPSs and tailoring enzymes [10]. Interestingly, a single hassallidin gene cluster encoded in the biosynthetic pathway for more than 40 chemical variants of hassallidin in Anabaena sp. SYKE748A [10].
Invasive fungal infections caused by Candida spp. and Aspergillus spp. are common, especially in immunocompromised patients. The increase of antifungal resistance indicates an urgent need for new antifungal compounds [11,12,13]. Here, we screened cyanobacteria for antifungal compounds, and we were able to detect known, but also potential new antifungal natural products.

2. Results and Discussion

2.1. Cyanobacteria Producing Antifungal Compounds

We screened 194 cyanobacterial strains isolated from brackish water, freshwater and terrestrial habitats using a disc diffusion assay (Table 1, Supplementary Table S1). Freeze-dried cells of cyanobacteria were extracted with methanol and were tested by the disc diffusion assay against Candida albicans and/or Aspergillus flavus. Ten strains were found to produce bioactive compounds inhibiting Candida albicans and nine inhibiting Aspergillus flavus (Table 1, Supplementary Figure S1). These eleven strains with antifungal compounds were analyzed using LC-MS.
Table 1. Cyanobacterial strains producing antifungal compounds according to the disc diffusion assay.
Table 1. Cyanobacterial strains producing antifungal compounds according to the disc diffusion assay.
Cyanobacteria16S rRNA GeneOriginInhibited Organism(s)Antifungal Compound
Nostoc sp. CENA 219KP701037Benthic freshwater, BrazilCa/Afhassallidin
Anabaena sp. BIR JV1KP701036The Gulf of FinlandCahassallidin
Anabaena sp. HAN7/1KP701033Epilithic, FinlandCahassallidin
Nostoc calcicula 6 sf CalcKP701034Dobre Pole, Czech RepublicCa/Afhassallidin
Anabaena sp. HAN21/1KP701032Gastropod, FinlandCa/Afscytophycin
Anabaena cf. cylindrica PH133AJ293110Lake Arresø, DenmarkCa/Afscytophycin
Scytonema sp. HAN3/2KP701039Green biofilm in the pond, FinlandCa/Afscytophycin
Nostoc sp. HAN11/1KP701035Small pond on a rock, FinlandCa/Afscytophycin
Fischerella sp. CENA 298KP701038Soil, BrazilCa/Afunidentified
Scytonema hofmanni PCC 7110NR112180Limestone, BermudaCa/Afunidentified
Nostoc sp. N107.3KP701040Lichen, FinlandAfunidentified
Ca = Candida albicans; Af = Aspergillus flavus.
Antifungal compounds in Anabaena sp. HAN21/1, Anabaena cf. cylindrica PH133, Nostoc sp. HAN11/1 and Scytonema sp. HAN3/2 were identified to be scytophycins (Sc) with LC-MS. The identification based on the molecular masses of the compounds showed losses of multiple 32-Da neutral fragments (typical for aliphatic methoxy groups containing compounds). In addition, the 15N-labeling experiments of Anabaena sp. HAN21/1 showed that these compounds contained a single nitrogen atom (Supplementary Figure S2). To confirm the identity of these compounds, the main antifungal compound of Anabaena sp. HAN21/1 was isolated by HPLC. NMR analysis (Supplementary Figures S3 and S4 and Table S2) showed that this compound was 7-OMe-Sc-B (1, Figure 1). The NMR sample contained also another compound scytophycin analog 2, the structure of which can be derived from 7-OMe-Sc-B via the photocatalytic Paternò–Büchi reaction (Figure 1). This 7-OMe-Sc-B preparation presented a MIC/IC50 of 0.33/0.16 mg·mL−1 (0.40/0.19 mM) for Candida albicans HAMBI 484 and 0.67/0.29 mg·mL−1 (0.80/0.23 mM) for Candida guilliermondii HAMBI 257.
Several scytophycin variants were identified from strains Anabaena sp. HAN21/1, Anabaena cf. cylindrica PH133, Nostoc sp. HAN11/1 and Scytonema sp. HAN3/2 (Figure 2, Table 2 and Supplementary Table S3). These strains produced known and previously unreported scytophycins variants (Table 2 and Supplementary Table S3 and S4), and their identification was based on the existence of prominent [M + Na]+ and also often [M + H − H2O]+ ions with masses at the range of reported scytophycins (Supplementary Figure S2) and of the characteristic product ion spectra of [M + Na]+ (example spectrum from 7-OMe-Sc-B in Supplementary Figure S5). Detailed mass spectrometric structural analysis turned out to be challenging. Protonated dehydrated scytophycins generated product ion spectra full of ions for which many represent the loss of water and methanol (32 Da), and hence, they were of small value for the determination of the structure (Supplementary Figure S6). Nitrogen labeling confirmed that the even number product ions contained the nitrogen atom of the scytophycins (Supplementary Figures S6 and S7). Product ion spectra from sodiated scytophycins were more structurally informative, showing fewer product ions, as seen from the spectrum of sodiated 7-OMe-Sc-B (Supplementary Figure S5). Nitrogen labeling again confirmed the presence of nitrogen in the product ions (Supplementary Figure S7). The base peaks in the scytophycin product ion spectra (for example, m/z 620 from 7-OMe-Sc-B) and ion m/z 262 contained nitrogen (Supplementary Figure S7). Based on the aforementioned data, the tentative fragmentation and structure of 33 scytophycins are presented in Supplementary Tables S3 and S5.
Figure 1. 7-OMe-scytophycin-B (1) isolated from Anabaena sp. HAN21/1 and 7-OMe-scytophycin-B reacted by light (2) after the Paternò–Büchi reaction. Stereochemistry is according to the literature.
Figure 1. 7-OMe-scytophycin-B (1) isolated from Anabaena sp. HAN21/1 and 7-OMe-scytophycin-B reacted by light (2) after the Paternò–Büchi reaction. Stereochemistry is according to the literature.
Marinedrugs 13 02124 g001
Figure 2. Total ion current chromatograms of methanol extracts of Scytonema sp. HAN3/2, Nostoc sp. HAN11/1, Anabaena sp. HAN21/1 and Anabaena cf. cylindrica PH133 showing the elution of scytophycin variants 1–33. Bolded numbers and arrows show the main scytophycin variants.
Figure 2. Total ion current chromatograms of methanol extracts of Scytonema sp. HAN3/2, Nostoc sp. HAN11/1, Anabaena sp. HAN21/1 and Anabaena cf. cylindrica PH133 showing the elution of scytophycin variants 1–33. Bolded numbers and arrows show the main scytophycin variants.
Marinedrugs 13 02124 g002
Table 2. Scytophycin variants, retention times (Rt), experimental (Exp) and calculated (Cal) [M + Na]+ ion masses (m/z), mass error in ppm (), formula and abundance (+, ++, +++), in the studied Scytonema sp. HAN3/2, Nostoc sp. HAN11/1, Anabaena sp. HAN21/1 and Anabaena cf. cylindrica PH133 strains. a Mass from [M + H − H2O]+, because [M + Na]+ was absent. New variants are indicated by “N” and in bold.
Table 2. Scytophycin variants, retention times (Rt), experimental (Exp) and calculated (Cal) [M + Na]+ ion masses (m/z), mass error in ppm (), formula and abundance (+, ++, +++), in the studied Scytonema sp. HAN3/2, Nostoc sp. HAN11/1, Anabaena sp. HAN21/1 and Anabaena cf. cylindrica PH133 strains. a Mass from [M + H − H2O]+, because [M + Na]+ was absent. New variants are indicated by “N” and in bold.
Strains
Scytophycin (Sc) variantRt (min)[M + Na]+ (m/z) HAN3/2HAN11/1HAN21/1PH133
No.Chemical variantExpCal∆ (ppm)Formula
10 N6-OH-7-OMe-15-O-deMe-Sc-B19.9858.5 ++
156-OH-7-OMe-Sc-D/E20.1874.5 ++
16 NX-OH-Sc-D/E (not 6-OH)20.3860.5116860.5131−1.70C45H75NO13++ +++
18Sc-D/E20.6844.5157844.5181−2.90C45H75NO12++ +++
19 NSc20.6814.5a ++
206-OH-7-OMe-Sc-B20.6872.5 ++++
22 NSc20.9842.5 ++ +
25Sc-B21.3842.5022842.5025−0.35C45H73NO12++++++++++
26 NSc, (-O from C15/16/17/19)21.9826.5062826.5076−1.67C45H73NO11++++++
27Sc-C22.4828.5221828.5232−1.37C45H75NO11+++++++
29 N7-OMe-29-OAc-Sc-B22.6884.5129884.5131−0.18C47H75NO13 ++
307-OMe-Sc-B (1)23.5856.5 ++++++++
31 N7-OMe-Sc, (-O from C15/16/17)24.0840.5 ++++
Fourteen variants of hassallidin (Figure 3) were detected in the Nostoc sp. CENA 219 methanol extract (Figure 4, Table 3). The hassallidin variants differ in the presence of sugars (pentose, deoxyhexose, hexose, acetylated hexose and N-acetylhexosamine), by the composition of the aglyconic peptide core structure and the fatty acid moiety (Table 3). The relative amounts of hassallidin variants can be roughly estimated from the TIC chromatograms presented in Figure 4. Variants 11, 15 and 26 are the most abundant hassallidins in Nostoc sp. CENA 219. They all have the same aglyconic lipopeptide structure m/z 1298 but the number of monosaccharides differs. N-acetylhexosamine was found only from the Brazilian Nostoc sp. CENA 219. Ten variants of hassallidins were detected in the Nostoc calcicula 6 sf Calc, nine variants from the Anabaena sp. BIR JV1 and Anabaena sp. HAN7/1 methanol extract (Figure 4, Table 3 and Supplementary Figures S9–S15). The main hassallidin variants found in the extract of Nostoc calcicula 6 sf Calc were 12, 14 and 15. The hassallidin 12 was also detected in the Anabaena spp. BIR JV1 and HAN7/1 and the hassallidin 15 in the Nostoc sp. CENA 219 cells extracts. Variants 12, 13 and 16 were the most abundant hassallidins in Anabaena sp. BIR JV1 and Anabaena sp. HAN7/1, respectively. They have the same aglyconic lipopeptide structure m/z 1,298 but the degree of acetylation on hexose in the position M3 varies (Figure 3). Altogether, hassallidin profiles of Anabaena sp. BIR JV1 and Anabaena sp. HAN7/1 were highly similar. The structure of the aglyconic lipopeptide m/z 1298 is unknown. The hassallidin structures have been deduced from the mass spectra presented in the Supplementary Figures S9–S15.
Figure 3. The general chemical structure of hassallidin. M1–M3 are monosaccharides, R1 is the hydrocarbon chain of the fatty acid chain FA1 and R2–R10 side chains of amino acids Aa2 to Aa10.
Figure 3. The general chemical structure of hassallidin. M1–M3 are monosaccharides, R1 is the hydrocarbon chain of the fatty acid chain FA1 and R2–R10 side chains of amino acids Aa2 to Aa10.
Marinedrugs 13 02124 g003
Figure 4. Total ion current chromatograms of methanol extracts of Nostoc sp. CENA 219, Nostoc calcicula 6 sf Calc, Anabaena sp. HAN7/1 and Anabaena sp. BIR JV1 showing the elution of hassallidin variants 1–27.
Figure 4. Total ion current chromatograms of methanol extracts of Nostoc sp. CENA 219, Nostoc calcicula 6 sf Calc, Anabaena sp. HAN7/1 and Anabaena sp. BIR JV1 showing the elution of hassallidin variants 1–27.
Marinedrugs 13 02124 g004
Table 3. Retention times (Rt), ion masses and monosaccharide (M1, M2 and M3) content of hassallidin variants in Nostoc sp. CENA 219, Nostoc calcicula 6 sf Calc, Anabaena sp. HAN7/1 and Anabaena sp. BIR JV1 strains. The major variants produced are highlighted in grey.
Table 3. Retention times (Rt), ion masses and monosaccharide (M1, M2 and M3) content of hassallidin variants in Nostoc sp. CENA 219, Nostoc calcicula 6 sf Calc, Anabaena sp. HAN7/1 and Anabaena sp. BIR JV1 strains. The major variants produced are highlighted in grey.
Strains
RtIon masses (m/z)MonosaccharidesCENA 2196sf CalcHAN7/1BIR JV1
No(min)AL [M + H]+[M + Na]+M1M2M3
13.11296.61815.8HexNAcPentHexx
23.51294.81813.7HexNAcPentHexx
35.91280.71799.8HexNAcPentHexx
46.21280.71772.8HexdHexHex xxx
56.51278.61797.8HexNAcPentHexx
66.81280.71814.9HexdHexAcHex x
77.21314.71833.7HexNAcPentHexx
811.91270.71789.7HexNAcPentHexx
913.71236.71728.8HexdHexHex xx
1017.71282.71801.9HexNAcPentHexx
1118.31298.71817.8HexNAcPentHexx
1218.41298.71790.6HexdHexHex xxx
1318.81298.71832.8HexdHexAcHex xx
1418.91298.71790.8HexdHexHex x
1519.31298.61614.7 PentHexxx
1619.61298.71874.8HexdHexdiAcHex xx
1720.21264.71783.9HexNAcPentHexx
1820.31264.71756.6HexdHexHex xx
1920.51298.71628.7 dHexHex x
2020.91264.71756.8HexdHexHex x
2121.01298.71916.8HexdHextriAcHex xx
2221.41264.71580.8 PentHexxx
2322.51280.61958.7HexdHextetraAcHex xx
2422.71266.71785.8HexNAcPentHexx
2522.71298.71452.7 Pent x
2623.91298.71482.7 Hexxx
2726.31264.71448.7 Hexxxx
AL = Aglyconic lipopeptide containing substructures FA1 and Aa2–Aa10, HexNAc = N-acetylhexosamine (residue mass 203 Da), Pent = pentose (132), dHex = deoxyhexose (146), Hex = hexose (162), tetra/tri/di/AcHex = tetra-, tri-, di- or monoacetylhexose (330, 288, 246, 204).
The methanol extract of Scytonema hofmanni PCC 7110 was fractionated by HPLC and tested against Aspergillus flavus. However, the bioactivity was lost during the re-isolation of the fraction containing the antifungal compound.

2.2. Evolutionary Relation of the Cyanobacterial Strains Producing Antifungal Compounds

A phylogenetic tree was constructed based on partial 16S rRNA gene sequences of the cyanobacteria producing antifungal compounds and other strains retrieved from the NCBI database (Figure 5). Analyzing the Anabaena sp. HAN21/1 16S rRNA gene sequence similarity of 99% with Anabaena cf. cylindrica PH133 in GenBank (NCBI) compelled us to check if this strain could produce scytophycin. Interestingly, through the phylogenetic analysis, we found another Anabaena strain isolated from a different environment producing scytophycins.
Figure 5. The distribution of cyanobacterial strains producing antifungal compounds. The neighbor-joining phylogenetic tree is based on the 16S rRNA genes sequences constructed with 1000 bootstraps in which the percentages over 50 are indicated in each node. Studied strains are in bold.
Figure 5. The distribution of cyanobacterial strains producing antifungal compounds. The neighbor-joining phylogenetic tree is based on the 16S rRNA genes sequences constructed with 1000 bootstraps in which the percentages over 50 are indicated in each node. Studied strains are in bold.
Marinedrugs 13 02124 g005

2.3. Discussion

The screening for antifungal compounds produced by cyanobacteria led us to discover new strains producing scytophycins and hassallidins. Antifungal compounds were detected from strains belonging to the Nostocales and Stigonematales orders, such as Anabaena, Fischerella, Nostoc and Scytonema. Phylogenetic analysis based on 16S rRNA gene sequences shows that the studied strains are widely distributed in the tree (Figure 5). It is common to have non-producers and producers of bioactive compounds grouped together in phylogenetic trees [14,15]. We first detected Anabaena sp. HAN21/1, isolated from a gastropod living in brackish water in the coast of Finland, producing scytophycins. The comparison of the 16S rRNA gene sequence of this strain with other sequences in the NCBI led us to investigate if the first hit, Anabaena cf. cylindrica PH133, could also produce scytophycin. Surprisingly, we detected Anabaena cf. cylindrica PH133, isolated from freshwater of Lake Arresø in Denmark producing scytophycins. Interestingly, this is the first report to our knowledge of Anabaena strains producing scytophycins. Two other benthic cyanobacteria from the Baltic Sea coast, Nostoc sp. HAN11/1 and Scytonema sp. HAN3/2, were also detected to produce scytophycin (Table 1 and Table 2).
The studied strains produced a diverse variety of scytophycin, including scytophycin B, C, D/E (Table 2). Scytophycins have been previously reported to be produced by Scytonema spp. [16,17], Cylindrospermum [18] and Nostoc sp. 5/96 [19]. Tolytoxin, which was first detected in Tolypothrix conglutinata var. colorata, is also known as 6-hydroxy-7-O-methyl-scytophycin B [16,17]. Fourteen scytophycin variants have been described by other authors before, in which the six variable positions reported are C-6, -7, -16, -19, -23 and -27 (Supplementary Table S4). The main chemical variant isolated from Anabaena sp. HAN21/1 was 7-OMe-scytophycin-B, which had been previously reported from Nostoc sp. 5/96 [19]. Nitrogen labeling of Anabaena sp. HAN21/1 confirmed the presence of nitrogen in the product ions. The base peaks in the scytophycin product ion spectra (for example, m/z 620 from 7-OMe-Sc-B) and ion m/z 262 contained nitrogen (Supplementary Figure S7). However, the product ions structures for ion m/z 262 and m/z 620 reported in Tomsickova et al., 2013, did not contain nitrogen, which is missing from the scytophycin structures that they reported. The Scytonema, Tolypothrix, Cylindrospermum and Nostoc strains described to produce scytophycins were all isolated from terrestrial habitats [18,19].
Scytophycins are macrolides polyketides, but the biosynthetic genes involved in their synthesis are unknown. Other compounds that have been described to be structurally related to scytophycins are lobophorolide [20], swinholides, aplyronine, sphinxolides/reidispongiolides and ulapualides/kabiramide/halichondramides/mycalolides [21]. Aplyronine A, sphinxolide, mycalolide A and ulapualide A have very similar side chains to scytophycins, with all presenting an N-methylvinylformamide [21]. Interestingly, these compounds have been found in other organism than cyanobacteria: seaweed Lobophora variegate, a symbiont in the red sea sponge Theonella swinhoei, sea hare Aplysia kurodai, an unidentified nudibranch, marine sponges Neosiphonia superstes and Reidispongia coerulea, egg masses of the nudibranch Hexabranchus sanguineas, sponges Halichondria sp. and Mycale spp. and hard coral Tubastraea faulkneri [21]. Swinholide A, scytophycins, sphinxolide, ulapualides, mycolides and aplyronine A have potent cytotoxicity against cancer cell lines [21]. Interestingly, tolytoxin has been proposed to play an ecological role in the defense system of Scytonema ocellatum [22]. The cyanobacteria increased the synthesis of tolytoxin when in the presence of the fungal cell-wall polysaccharide chitin [22].
We report for the first time to our knowledge a variant of the scytophycin isolated from Anabaena sp. HAN21/1, which can be altered after a Paternò–Büchi reaction catalyzed by light (Figure 1). This photochemical reaction modifies the side chain and probably was responsible for the loss of activity of 7-OMe-scytophycin-B.
Hassallidins are lipopeptides produced by nonribosomal biosynthetic enzymes in cyanobacteria [10,23,24]. Hassallidins have been detected previously in Cylindrospermopsis, Anabaena, Aphanizomenon, Nostoc, Tolypothrix and Hassalia [10,23,24]. In this study, diverse variants of hassallidins were detected in methanol extracts from strains Nostoc spp. 6 sf Calc and CENA 219 and Anabaena spp. BIR JV1 and HAN7/1 (Table 3).
The Nostoc sp. CENA 219 hassallidins’ (Table 3) monosaccharide composition was similar to Nostoc sp. 113.5 monosaccharides [10], but the aglyconic lipopeptide structures were more variable in the present studied strains. Nostoc calcicula 6 sf Calc hassallidin structures were similar to Nostoc sp. 159 and Tolypothrix sp. PCC 9009 hassallidin structures (Supplementary Material in [10]). Anabaena sp. BIR JV1 and Anabaena sp. HAN7/1 hassallidins (Table 3) monosaccharide composition was similar to Anabaena spp. XPORK 5C, XSPORK 7B and BECID 19 monosaccharides [10], but the aglyconic lipopeptide structures were more variable in the strains in the present study. The detailed aglyconic lipopeptide structure is difficult to analyze reliably from the product ion spectrum of the aglyconic lipopeptide ion and could be determined by NMR analysis of purified hassallidin variants. Alternatively, the study of the substrate specificities of the adenylation domains of the hassallidin genes N, O, V and Y could be used to predict which amino acids are incorporated into the peptide [10].
Balticidins belongs to the family of hassallidin compounds, and they have been recently detected in Anabaena cylindrica Bio33 [25]. Balticidins are cyclic or linear peptides that differ from hassallidin by the presence of arabinose and galacturonic acid and the possible presence of chlorine in the fatty acid chain [25]. Hassallidins and balticidins are known for their activity against Candida spp. [10,25,26]. Hassallidins A and B were found to be active against Cryptococcus neoformans, Aspergillus spp., Fusarium spp., Penicillium sp., Ustilago maydis and Acremonium strictum [26]. In addition, hassallidins A and B were active against human acute T-cell leukemia (Jurkat ATCC-TIB-152) and murine aneuploid fibrosarcoma (L 929) [26]. Hassallidin D was shown to be a more potent antifungal than hassallidin A and B [10]. However, several variants of hassallidins are produced in trace amounts by the cyanobacteria, and the heterologous expression or syntheses of these variants is necessary to evaluate the activity of these compounds. The high amount of variants of hassallidins discovered recently highlights the potential of cyanobacteria for the synthesis of antifungal compounds. There is a need for further studies to analyze the potential of these new variants as antifungal and anticancer drugs.
Our screening study also revealed cyanobacterial strains producing unidentified antifungal compounds. Fischerella sp. CENA 298, Scytonema hofmanni PCC 7110 and Nostoc sp. N107.3 presented antifungal activity. LC-MS analysis of methanol crude extracts and isolated compounds by HPLC did not reveal insights into the chemical structure of these antifungal compounds. Further analyses are necessary for isolation and characterization of these bioactive compounds.

3. Experimental Section

3.1. Cultivation of Cyanobacterial Strains

The cyanobacterial strains were cultivated in Z8 medium [27] with or without a nitrogen source, in BG-11 [28] with, without or containing half of the amount of nitrogen, AA (Allen and Arnon) medium [29] or ASM medium [30]. The strains were cultivated in the specific medium (40–3000 mL) at 17 °C–25 °C under continuous light of 3–15 μmol·m−2·s−1. The strain Anabaena sp. HAN21/1 was labeled with 15N and analyzed with LC/MS, as previously described [31].

3.2. Extraction of Intracellular Cyanobacterial Compounds

The cells analyzed were obtained either from a 40-mL culture centrifuged at 8000× g for 5 min or from freeze-dried biomass (up to 100 mg). The fresh culture cells from the 40 mL of medium were extracted with 1 mL of methanol and glass beads (0.5-mm diameter glass beads, Scientific Industries INC) using a FastPrep cell disrupter instrument three times for 30 s at a speed of 6.5 m·s−1. The samples were centrifuged for 10,000× g for 5 min at room temperature and kept in a glass tube. The cells were extracted a second time using another 1 mL of methanol, as described before, and both methanol extracts were combined and dried with a stream of air. Residues were re-suspended in 200 μL of methanol, sonicated (Sonorex super 10P, Bandelin, Berlin, Germany) and kept at −20 °C for further analysis. A total of 100 mg of the freeze-dried biomass were extracted two times with 1 mL of methanol, as described before. The obtained supernatant was reserved for further analysis.

3.3. Disc Diffusion Assay

Methanol extracts (100–400 μL) from all of the studied strains were applied to a paper disc (Abtek Biologicals Ltd., Liverpool, United Kingdom). Candida albicans HAMBI261 was grown in yeast and mold agar (YM) medium, while Candida albicans HAMBI484 and Aspergillus flavus HAMBI 829 were grown in potato dextrose agar (PDA) medium. The inoculum for the bioassay was prepared as previously described [10]. The discs containing crude extract were applied on the PDA or YM media plates containing Candida albicans HAMBI 261 or HAMBI 484 and/or Aspergillus flavus HAMBI 829. After a period of 24 h for yeast at 35 °C or 48 h at 28 °C for mold, the plates were analyzed for inhibition zones, which were measured including the paper disk diameter.

3.4. Chemical Analysis

The obtained methanol extracts that contained antifungal activity were studied by LC-MS (Agilent 1100 Series LC/MSD Trap XCT Plus, Agilent Technologies, Palo Alto, CA, USA). All samples were analyzed with the following protocol: Luna C8(2) column (150 × 4.60 mm, 5 μm, 100 Å, Phenomenex, Torrance, CA, USA) with two eluents (A: 0.1% HCOOH in water, Fluka, Sigma-Aldrich (St. Louis, MO, USA); and B: 2-propanol in 0.1% HCOOH, Optima® LC/MS quality, Fischer Scientific, Fair Lawn, NJ, USA), used in a linear gradient, where Eluent B increased from 5% to 100% in 35 min with flow rate of 0.15 mL·min−1 and an injection volume of 10 μL. The mass spectrometer trap drive value was 144.0 with a scan range of m/z 200–1100. Samples suggesting signs of hassallidins were re-analyzed with the following protocol: Luna C18(2) column with 0.1% HCOOH in water or acetonitrile was used in the linear gradient, where the concentration of the acetonitrile eluent was increased from 30% to 70% in 49 min with a flow rate of 0.15 mL·min−1 and an injection volume of 10 μL. The mass spectrometer trap drive value was 110 with a scan range of m/z 300–2200. These obtained UV-, MS- and MS2-product ion spectrums were analyzed.

3.5. Purification of Scytophycin

HPLC (HP 1100 Series, Agilent, with DAD) was used to isolate the main scytophycin variant from the methanol extract of strain Anabaena sp. HAN21/1. The methanol extract was evaporated to dryness, and the residue was dissolved in HPLC eluent (40% isopropanol, 60% 0.1% HCOOH; 700 μL of eluent to every 1 mL of methanol extract), which was then injected in 100-μL batches into the Luna C8(2) column (150 × 4.60 mm, 5 μm, 100 Å, Phenomenex, Torrance, CA, USA). The column was eluted isocratically with a flow rate of 0.75 mL·min−1. Peaks eluting at 13.5 min were collected and combined in one tube. The eluent was evaporated, and the residue was dissolved in methanol, which was applied to the SP column (Phenomenex Strata C18-E 55 μm, 70 Å, 5 g/20 mL Giga Tubes, Torrance, CA USA), eluted with methanol. Dried and [D6] DMSO-dissolved compound was analyzed with NMR.

3.6. NMR of Scytophycin

The NMR spectra of 7-OMe-scytophycin-B derivative (Figure 1, compound 2) were recorded on the Varian Inova 600 spectrometer equipped with a cryogenically-cooled 1H/13C/15N triple resonance probe head and an actively-shielded z-axis gradient system in [D6] DMSO at 301 K. The 1H spectrum was measured with 8 transients using 24,000 complex points, which corresponds to an acquisition time of 2 s. Two-dimensional homonuclear total correlation spectroscopy (TOCSY) and double-quantum filtered correlation spectroscopy (DQF-COSY) experiments were both measured with 8 transients per FID (free induction decay), using 300 and 2386 complex points in the t1 and t2 domains, which translates to acquisition times of 43 and 341 ms in the t1 and t2 domains. The 13C-1H heteronuclear single quantum coherence (HSQC) spectrum was acquired with 180 and 596 complex points in t1 (13C) and t2 (1H), using 16 transients per FID, corresponding to acquisition times of 6 and 85 ms in the 13C and 1H dimensions, respectively. The 13C heteronuclear multiple bond correlation (13C-HMBC) experiment was measured using 256 and 2380 complex points in t1 (13C) and t2 (1H). This corresponds to acquisition times of 7.1 and 340 ms in the 13C and 1H dimensions, respectively. The signals were accumulated with 128 transients. The long-range 1H-13C delay was set to optimize transfer for 6 Hz 1H-13C couplings.

3.7. Microdilution Assay of Scytophycin

The microdilution assay was performed against Candida albicans HAMBI484 and Candida guilliermondii HAMBI 257, as previously described [10]. The calculation for the minimum inhibitory concentration (MIC) and half maximum inhibitory concentration (IC50) is explained in detail in [10].

3.8. DNA Extraction, Sequencing and Phylogenetic Analysis

The DNA extraction of the strains containing antifungal compounds was obtained using the DNeasy Plant Mini Kit (Qiagen Gmbh, Hilden, Germany) or the E.Z.N.A SP Plant DNA Mini Kit (Omega Bio-Tek Inc., Norcross, GA, USA). The cells were homogenized in the FastPrep cell disrupter for 30 s at 6.5 ms−1 (repeated three times), then the DNA extraction was followed as described in the manufacturer’s instructions. The partial 16S rRNA gene was amplified by PCR, as previously described [15]. The fragments were cloned into a pCR®2.1-TOPO® vector (Invitrogen, Carslbad, CA, USA) and transformed to One Shot® Chemically Competent Escherichia coli TOP10 cells, as recommended by the manufacturer. Positive clones were found through PCR using the vector primers (M13F and M13R) and sequenced. The phylogenetic tree using the neighbor-joining method was obtained in MEGA 5.0 [32]. The Kimura 2-parameter model with 1000 bootstrap replications and gamma distributed rates among sites has been used to obtain the phylogenetic tree.

4. Conclusions

Cyanobacterial strains were detected producing the antifungal compounds scytophycins and hassallidins. In this study, we first described to our knowledge Anabaena spp. producing scytophycins. There is a huge potential for the discovery of new variants of known antifungal compounds (scytophycins and hassallidins) but also for potential new compounds produced by Fischerella sp. CENA 298, Scytonema hofmanni PCC 7110 and Nostoc sp. N107.3 which need to be further analyzed.

Supplementary Files

Supplementary File 1

Acknowledgments

We thank M.Sc. Lyudmila Saari for maintaining and handling the cyanobacteria strains. This work was supported by the grants from the Academy of Finland to KS (1258827, 1273798, 118637) and the State of São Paulo Research Foundation (FAPESP) to MFF (2013/09192-0). TKS was partially funded by the Graduate Program in Biotechnology and Molecular Biology, currently the Integrative Life Science Doctoral Program, the São Paulo Research Foundation (2009/13455-0), the Centre for International Mobility (TM-09-6506) and the Finnish Cultural Foundation. AH is funded by the Doctoral Program in Microbiology and Biotechnology. LL was a matching fund student at the Viikki Graduate Program in Bioscience, currently the Doctoral Program in Microbiology and Biotechnology, and financially supported by the China Scholarship Council.

Author Contributions

TKS, LL, JJ, MW and KS designed the study. TKS, AH and LL performed the screening for antifungal activity. TKS, AH, LL, JJ and MW performed the chemical analysis. TKS, AH, LL, JJ and MW analyzed the data. TKS, AH, LL, JJ, MW, DPF and KS wrote the article. AT, PP and APDA participated in the part of the collection of the data. PP, MFF and KS contributed reagents and equipment.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Whitton, B.A.; Potts, M. Introduction to cyanobacteria. In The Ecology of Cyanobacteria. Their Diversity in Time and Space; Whitton, B.A., Potts, M., Eds.; Kluwer Academic: Dodrecht, The Netherlands, 2000; pp. 61–120. [Google Scholar]
  2. Kaasalainen, U.; Fewer, D.P.; Jokela, J.; Wahlsten, M.; Sivonen, K.; Rikkinen, J. Cyanobacteria produce a high variety of hepatotoxic peptides in lichen symbiosis. Proc. Natl. Acad. Sci. USA. 2012, 109, 5886–5891. [Google Scholar] [CrossRef] [PubMed]
  3. Sønstebø, J.H.; Rohrlack, T. Possible implications of chytrid parasitism for population subdivision in freshwater cyanobacteria of the genus Planktothrix. Appl. Environ. Microbiol. 2011, 77, 1344–1351. [Google Scholar] [CrossRef] [PubMed]
  4. Rohrlack, T.; Christiansen, G.; Kurmayer, R. Putative antiparasite defensive system involving ribosomal and nonribosomal oligopeptides in cyanobacteria of the genus Planktothrix. Appl. Environ. Microbiol. 2013, 79, 2642–2647. [Google Scholar] [CrossRef] [PubMed]
  5. Kajiyama, S.; Kanzaki, H.; Kawazu, K.; Kobayashi, A. Nostofungicidine, an antifungal lipopeptide from the field-grown terrestrial blue-green alga Nostoc commune. Tetrahedron Lett. 1998, 39, 3737–3740. [Google Scholar] [CrossRef]
  6. Burja, A.M.; Banaigs, B.; Abou-Mansour, E.; Burgess, J.G.; Wright, P.C. Marine cyanobacteria—A prolific source of natural products. Tetrahedron 2001, 57, 9347–9377. [Google Scholar] [CrossRef]
  7. Abed, R.M.; Dobretsov, S.; Sudesh, K. Applications of cyanobacteria in biotechnology. J. Appl. Microbiol. 2009, 106, 1–12. [Google Scholar] [CrossRef] [PubMed]
  8. Cane, D.E.; Walsh, C.T.; Khosla, C. Harnessing the biosynthetic code: Combinations, permutations, and mutations. Science 1998, 282, 63. [Google Scholar] [CrossRef] [PubMed]
  9. Cane, D.E.; Walsh, C.T. The parallel and convergent universes of polyketide synthases and nonribosomal peptide synthetases. Chem. Biol. 1999, 6, R319–R325. [Google Scholar] [CrossRef] [PubMed]
  10. Vestola, J.; Shishido, T.K.; Jokela, J.; Fewer, D.P.; Aitio, O.; Permi, P.; Wahlsten, M.; Wang, H.; Rouhiainen, L.; Sivonen, K. Hassallidins, antifungal glycolipopeptides, are widespread among cyanobacteria and are the end-product of a nonribosomal pathway. Proc. Natl. Acad. Sci. USA 2014, 111, E1909–E1917. [Google Scholar] [CrossRef] [PubMed]
  11. Loeffler, J.; Stevens, D.A. Antifungal drug resistance. Clin. Infect. Dis. 2003, 36, S31–S41. [Google Scholar] [CrossRef] [PubMed]
  12. Khan, M.S.A.; Ahmad, I.; Aqil, F.; Owais, M.; Shahid, M.; Musarrat, J. Virulence and pathogenicity of fungal pathogens with special reference to Candida albicans. In Combating Fungal Infections; Ahmad, I., Owais, M., Shahid, M., Aqil, F., Eds.; Springer-Verlag: Berlin, Germany, 2010; pp. 21–45. [Google Scholar]
  13. World Health Organization. Antifungal drug resistance: The example of invasive Candidiasis. In Antimicrobial Resistance: Global Report on Surveillance; WHO Press: Geneva, Switzerland, 2014; pp. 62–65. [Google Scholar]
  14. Gugger, M.; Lyra, C.; Henriksen, P.; Couté, A.; Humbert, J.F.; Sivonen, K. Phylogenetic comparison of the cyanobacterial genera Anabaena and Aphanizomenon. Int. J. Syst. Evol. Microbiol. 2002, 52, 1867–1880. [Google Scholar] [CrossRef]
  15. Shishido, T.K.; Kaasalainen, U.; Fewer, D.P.; Rouhiainen, L.; Jokela, J.; Wahlsten, M.; Fiore, M.F.; Yunes, J.S.; Rikkinen, J.; Sivonen, K. Convergent evolution of [d-Leucine(1)] microcystin-LR in taxonomically disparate cyanobacteria. BMC Evol. Biol. 2013, 13, 86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Ishibashi, M.; Moore, R.E.; Patterson, G.M.L. Scytophycins, Cytotoxic and antimycotic agents from the cyanophyte Scytonema pseudohofmanni. J. Org. Chem. 1986, 51, 5300–5306. [Google Scholar] [CrossRef]
  17. Carmeli, S.; Moore, R.E.; Patterson, G.M.L. Tolytoxin and new scytophycins from three species of Scytonema. J. Nat. Prod. 1990, 53, 1533–1542. [Google Scholar] [CrossRef] [PubMed]
  18. Jung, J.H.; Moore, R.E.; Patterson, G.M.L. Scytophycins from a blue-green alga belonging to the nostocaceae. Phytochemistry 1991, 30, 3615–3616. [Google Scholar] [CrossRef]
  19. Tomsickova, J.; Ondrej, M.; Cerny, J.; Hrouzek, P.; Kopecky, J. Analysis and detection of scytophycin variants by HPLC-ESI-MS. Chem. Nat. Compd. 2014, 49, 1170–1171. [Google Scholar] [CrossRef]
  20. Kubanek, J.; Jensen, P.R.; Keifer, P.A.; Sullards, M.C.; Collins, D.O.; Fenical, W. Seaweed resistance to microbial attack: A targeted chemical defense against marine fungi. Proc. Natl. Acad. Sci. USA 2003, 100, 6916–6921. [Google Scholar] [CrossRef]
  21. Yeung, K.-S.; Paterson, I. Actin-binding marine macrolides: Total synthesis and biological importance. Angew. Chem. Int. 2002, 41, 4632–4653. [Google Scholar] [CrossRef]
  22. Patterson, G.M.L.; Bolis, C.M. Fungal cell wall polysaccharides elicit an antifungal secondary metabolite (phytoalexin) in the cyanobacterium Scytonema ocelutum. J. Phycol. 1997, 33, 54–60. [Google Scholar] [CrossRef]
  23. Neuhof, T.; Schmieder, P.; Preussel, K.; Dieckmann, R.; Pham, H.; Bartl, F.; von Döhren, H. Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp. J. Nat. Prod. 2005, 68, 695–700. [Google Scholar] [CrossRef] [PubMed]
  24. Neuhof, T.; Schmieder, P.; Seibold, M.; Preussel, K.; von Döhren, H. Hassallidin B—Second antifungal member of the Hassallidin family. Bioorg. Med. Chem. Lett. 2006, 16, 4220–4222. [Google Scholar] [CrossRef] [PubMed]
  25. Bui, T.H.; Wray, V.; Nimtz, M.; Fossen, T.; Preisitsch, M.; Schröder, G.; Wende, K.; Heiden, S.E.; Mundt, S. Balticidins A-D, antifungal hassallidin-like lipopeptides from the Baltic Sea cyanobacterium Anabaena cylindrica Bio33. J. Nat. Prod. 2014, 77, 1287–1296. [Google Scholar] [CrossRef] [PubMed]
  26. Neuhof, T.; Dieckmann, R.; von Döhren, H.; Preussel, K.; Seibold, M.; Schmieder, P. Lipopeptides Having Pharmaceutical Activity. Patent Analysis 1698638 EP, 8 September 2006. [Google Scholar]
  27. Kótai, J. Instructions for Preparation of Modified Nutrient Solution Z8 for Algae; NIVA B-11/69; Norwegian Institute for Water Research: Blindern, Oslo, Norway, 1972. [Google Scholar]
  28. Allen, M.B. Simple conditions for growth of unicellular blue-green algae on plates. J. Phycol. 1968, 4, 1–4. [Google Scholar] [CrossRef]
  29. Allen, M.M.; Arnon, D.I. Studies on nitrogen-fixing blue-green algae. I. Growth and nitrogen fixation by Anabaena cylindrical Lemm. Plant Physiol. 1955, 30, 366–372. [Google Scholar] [CrossRef] [PubMed]
  30. Gorham, P.R.; McLachlan, J.; Hammer, U.T.; Kim, W.K. Isolation and culture of toxic strains of Anabaena flos-aquae (Lyngb.) de Bréb. Verh. Int. Verein. Theor. Angew. Limnol. 1964, 15, 796–804. [Google Scholar]
  31. Jokela, J.; Oftedal, L.; Herfindal, L.; Permi, P.; Wahlsten, M.; Døskeland, S.O.; Sivonen, K. Anabaenolysins, novel cytolytic lipopeptides from benthic Anabaena cyanobacteria. PLoS ONE 2012, 7, e41222. [Google Scholar] [CrossRef] [PubMed]
  32. Tamura, K.; Peterson, D.; Peterson, N.; Stecher, G.; Nei, M.; Kumar, S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28, 2731–2739. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Shishido, T.K.; Humisto, A.; Jokela, J.; Liu, L.; Wahlsten, M.; Tamrakar, A.; Fewer, D.P.; Permi, P.; Andreote, A.P.D.; Fiore, M.F.; et al. Antifungal Compounds from Cyanobacteria. Mar. Drugs 2015, 13, 2124-2140. https://doi.org/10.3390/md13042124

AMA Style

Shishido TK, Humisto A, Jokela J, Liu L, Wahlsten M, Tamrakar A, Fewer DP, Permi P, Andreote APD, Fiore MF, et al. Antifungal Compounds from Cyanobacteria. Marine Drugs. 2015; 13(4):2124-2140. https://doi.org/10.3390/md13042124

Chicago/Turabian Style

Shishido, Tânia K., Anu Humisto, Jouni Jokela, Liwei Liu, Matti Wahlsten, Anisha Tamrakar, David P. Fewer, Perttu Permi, Ana P. D. Andreote, Marli F. Fiore, and et al. 2015. "Antifungal Compounds from Cyanobacteria" Marine Drugs 13, no. 4: 2124-2140. https://doi.org/10.3390/md13042124

APA Style

Shishido, T. K., Humisto, A., Jokela, J., Liu, L., Wahlsten, M., Tamrakar, A., Fewer, D. P., Permi, P., Andreote, A. P. D., Fiore, M. F., & Sivonen, K. (2015). Antifungal Compounds from Cyanobacteria. Marine Drugs, 13(4), 2124-2140. https://doi.org/10.3390/md13042124

Article Metrics

Back to TopTop